Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification

BACKGROUND: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare type of non-small cell lung cancer (NSCLC). Currently, anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) has become an important treatment for NSCLC. Anti-human PD-1 monoclonal antibodies, such as nivoluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanyang, Long, Lang, Liu, Jiewei, Zhu, Lingling, Luo, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531585/
https://www.ncbi.nlm.nih.gov/pubmed/34692530
http://dx.doi.org/10.3389/fonc.2021.749682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531585/
https://www.ncbi.nlm.nih.gov/pubmed/34692530
http://dx.doi.org/10.3389/fonc.2021.749682

Ejemplares similares